BMS Signs an Exclusive Global License with Agenus for its Anti-TIGIT Bispecific Antibody Program
Shots: Agenus to receive a $200M as up front & ~$1.36B as development, regulatory and commercial milestones plus royalties on net sales of the therapies. Agenus will retain options to conduct clinical studies and combination studies with other pipeline assets and to co-promote AGEN1777 in the US BMS will be solely responsible for the development […]